Consensus sites for p53 binding [21] have been identified in intronic regions of the IGFBP3 gene [22], and wild-type p53 has been shown to upregulate IGFBP-3 following treatment with the DNA damaging agent doxorubicin in HeLa cervical cancer cells [22]. This evidence concerns the gene IGFBP3 and cervical cancer.